Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Marnix Wieffer

Marnix Wieffer

Drug Safety Information Specialist

About the author: As drug safety information specialist, I support pharmaceutical companies in identifying potential drug toxicity concerns and adverse effects. During my first 3 years at Elsevier, I have been working with both academic and corporate customers in northern Europe. As senior marketing manager, I am currently responsible for Elsevier’s drug safety messaging, internal training and market engagement.

Posts by Marnix Wieffer

PharmaPendium team collaborates with pharma companies on drug-drug interaction risk calculator

Posted on December 11th, 2019 in Pharma R&D


When taking a new drug, most patients’ chief concern is whether or not that drug is going to have the intended effect. They aren’t always thinking about what other drugs they might already be taking, and how those drugs could be affected by the new one.


FDA collaborates with Elsevier on drug-induced liver injury (DILI) tool

Posted on December 3rd, 2019 in Pharma R&D

A leading cause of attrition of compounds in drug development, drug-induced liver injury (DILI) is also one of the top causes of drug withdrawals, restrictions and project terminations. DILI results when reactive metabolites – formed when certain orally administered drugs are metabolized in the liver – end up binding to cellular proteins and damaging liver cells.


Improving the speed and ease of collecting pharmacovigilance data

Posted on June 12th, 2019 in Pharma R&D

Learn how the staff of biotechnology company 4P-Pharma uses Elsevier’s Embase to address challenges in conducting clinical trials.


  1. 1
  2. 2